NCT01267955 2026-03-18
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT02581930 2025-09-08
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02631746 2025-03-14
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00735917 2019-04-02
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00245063 2014-10-02
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01217398 2013-08-26
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00036764 2013-01-25
BMS-247550 in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025363 2013-01-17
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00884767 2009-07-08
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Phase 2 Unknown